<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 3; Issue 6</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Nov-Dec, 2022)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>A Debilitating Adverse Reaction of Pityriasis Rubra Pilaris Due to Statin Therapy in A Low-Risk Patient: Case Report</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>7</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Reich</FirstName>
          <LastName>IJ</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Keller</FirstName>
          <LastName>KL</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>A 57-year-old male cardiologist with no previous cardiac history nor a positive family history of cardiovascular disease was started on atorvastatin to treat an LDL of 140 mg/dL. Within one month he developed a debilitating dermatologic reaction that initially was thought to be life-threatening Stevens-Johnson Syndrome. Biopsy demonstrated the reaction was Pityriasis Rubra Pilaris (PRP) an incurable dermatologic disease which on average lasts more than a year before resolution. As of the writing of this case report, 6 months after starting atorvastatin, the symptoms persist. This is only the second reported case of PRP resulting from statin therapy.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Statin,Pityriasis Rubra Pilaris,Lipid Therapy</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=14156&amp;title=A Debilitating Adverse Reaction of Pityriasis Rubra Pilaris Due to Statin Therapy in A Low-Risk Patient: Case Report</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018; 15: 757-769.&#13;
&#13;
Cholesterol Treatment Trialistsand;#39; (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.&#13;
&#13;
Gajinov ZT, Matic MB, Duran VD, Vuckovic N, Prcic ST, Vujanovic LM. Drug-related pityriasis rubra pilaris with acantholysis. Vojnosanit Pregl 2013; 70: 871-873.&#13;
&#13;
Hippisley-Cox J and Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study. Heart 2010; 96: 939-947.&#13;
&#13;
Noordally SO, Sohawon S, Vanderhulst J, Duttmann R, Corazza F, Devriendt J. A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis. Ann Saudi Med 2012; 32: 309-311.&#13;
&#13;
Quick Stats. Percentage of adults &gt; 20 years of age told their cholesterol was high taking lipid lowering medication, by sex and age group. Morb Mort Weekly Report 2018; 67,771.&#13;
&#13;
Redberg R and Katz M. Healthy Men Should Not Use Statins. JAMA 2012; 307: 1491-1492.&#13;
&#13;
Simons JE, Holbrook AM, Don-Wauchope AC. Successful reintroduction of statin therapy after statin-associated rhabdomyolysis. J Clin Lipidol 2015; 9: 594-596.&#13;
&#13;
Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Cochrane Database Syst Rev 2011; 8: CD007551&#13;
&#13;
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 1: CD004816.&#13;
&#13;
Web-links:&#13;
&#13;
&#13;
	Hurst TR. Considering statins? What a Cardiologist wants you to know. WebMD. Available at: https://blogs.webmd.com/heart-health/20210121/considering-statins-what-a-cardiologist-wants-you-to-know#&#13;
	Batts V. Statins: A billion-dollar industry costing millions of lives. Statins.com. Available at: https://www.statins.news/2019-04-08-statins-a-billion-dollar-industry-costing-millions-of-lives.html&#13;
	Abramason J. Statins in patients at low risk of cardiac disease. Am Fam Physician 2017; 96: Available at: https://www.aafp.org/afp/2017/1101/od1.html.&#13;
	National Organization for Rare Disorders, Rare Disease Database, Pityriasis Rubra Pilaris, Pityriasis Rubra Pilaris - NORD (National Organization for Rare Disorders) Available at: https://rarediseases.org/rare-diseases/pityriasis-rubra-pilaris/&#13;
	NY Times. October 18, 2018.&#13;
	Available at: https://www.nytimes.com/2021/10/18/well/live/ldl-cholesterol-heart-attack.html#commentsContainer</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>